Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GelTex Pharmaceuticals (GELX) -- Ignore unavailable to you. Want to Upgrade?

To: James Silverman who wrote (34)	10/24/1997 5:00:00 PM
From: NY0001	Read Replies (1) \| Respond to of 127

Thanks for the quick reply. I am just learning about biotech and pharmaceutical investments and I am fascinated by them. Based on your message above I also looked into KOSP. What do you know about it and how does it compare to GELX? Have you read the Schroders (European office in London)report on neutraceuticals? Would you classify any of KOSP's products as neutriceuticals? Why do you think that a Johnson & Johnson (McNeil Consumer Products sub.) licensed Raisio's Benecol product for the US? Do you see the big pharma companies moving into the nutraceuticals and food supplement markets to try and have an affect on vertical products in the same market? How would KOSP's niacin based products compare to Benecol or the Phytrol product Forbes Medi-Tech has in clinical trials with one of the world's largest food manufacturers? Wouldn't they have reviewed KOSP's technology before going with the others? Is KOSP going to stay in the food supplement business in addition to pharmaceuticals? Any thoughts or analysis is helpful.